Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCC vs BCG in first-line high-risk non-muscle invasive bladder cancer
NCT01284205Phase 3Withdrawn
- Sponsor
- Bioniche Life Sciences
- Start
- Jan 2010
- Primary completion
- Feb 2014
- Modality
- Biologic, CWE (Cell wall extract)
- Countries
- 1
01
Overview
A Phase 3 trial of mycobacterial cell wall-DNA complex in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Bioniche Life Sciences. Planned start Jan 2010; status: withdrawn.
02
Drugs
mycobacterial cell wall-DNA complex
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT01284205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01284205.